Additionally, the artemisinin derivative ADART exhibits potent efficacy in MS models, inhibiting IFN-γ and IL-17 production in vitro, reducing the ratios of Th1 and Th17 cells, and lowering the levels of IFN-γ and IL-17A in vivo, further contributing to disease attenuation [165]. This evidence concerns the gene IL17A and myeloid sarcoma.